Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions

References

• Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide. Histochemie 1966;7:197–201
   PubMedGoogle Scholar
• Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829–35
   PubMedGoogle Scholar
• Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in the anesthetized pig. Diabetes 1998;47:764–9
   PubMed Web of Science ®Google Scholar
• Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998;47:1663–70
   PubMed Web of Science ®Google Scholar
• Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003;10:19–25
   PubMedGoogle Scholar
• Hiramatsu H, Kyono K, Higashiyama Y, et al. The structure and function of human dipeptidyl peptidase IV, possessing a unique eight-bladed β-propeller fold. Biochem Biophys Res Commun 2003;302:849–54
   PubMed Web of Science ®Google Scholar
• Thoma R, Loffler B, Stihle M, et al. Structure basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. Structure 2003;11:947–59
   PubMed Web of Science ®Google Scholar
• Engel M, Hoffmann T, Wagner L, et al. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci USA 2003;100:5063–8
   PubMed Web of Science ®Google Scholar
• Oefner C, Arcy AD, Sweeney AM, et al. High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[({2-[5-iodopyridin-2-yl)amino]-ethyl}amino)-acetyl]-2-cyano-(S)-pyrrolidine. Acta Crystallogr 2003;D59:1206–12
   Google Scholar
• Engel M, Hoffmann T, Manhart S, et al. Rigidity and flexibility of dipeptidyl peptidase IV: crystal structures of and docking experiments with DPIV. J Mol Biol 2006;355:768–83
   PubMed Web of Science ®Google Scholar
• Juillerat-Jeanneret L. Dipeptidyl peptidase IV and its inhibitor: therapeutics for type 2 diabetes and what else? J Med Chem 2014;57:2197–212
   PubMed Web of Science ®Google Scholar
• Nabeno M, Akahoshi F, Kishida H, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun 2013;434:191–6
   PubMed Web of Science ®Google Scholar
• Yoshida T, Akahoshi F, Sakashita H, et al. Fused bicyclic heteroarylpiperazine-substituted L-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group. Bioorg Med Chem 2012;20:5033–41
   PubMed Web of Science ®Google Scholar
• Kato N, Oka M, Murase T, et al. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidine-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-caroxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem 2011;19:7221–7
   PubMed Web of Science ®Google Scholar
• Kim D, Wang L, Beconi M, et al. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141–51
   PubMed Web of Science ®Google Scholar
• Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774–89
   PubMed Web of Science ®Google Scholar
• Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007;50:2297–300
   PubMed Web of Science ®Google Scholar
• Adachi H, Takano K, Hosokawa Y, et al. Laser irradiated growth of protein crystal. Jpn J Appl Phys 2003;42:L798–800
   Google Scholar
• Lebedev AA, Vagin AA, Murshudov GN. Model preparation in MOLREP and examples of model improvement using X-ray data. Acta Crystallogr 2008;D64:33–9
   Google Scholar
• Metzler WJ, Yanchunas J, Weigelt C, et al. Involvement of DPP-IV catalytic residues in enzyme–saxagliptin complex formation. Protein Sci 2008;17:240–50
   PubMed Web of Science ®Google Scholar
• Winn MD, Murshudov GN, Papiz MZ. Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol 2003;374:300–21
   PubMed Web of Science ®Google Scholar
• Glide version 6.1. New York (NY): Schrödinger, LLC; 2013
   Google Scholar
• Flack HD. On enantiomorph-polarity estimation. Acta Crystallogr 1983;A39:876–81
   Web of Science ®Google Scholar
• Tsuzuki S, Honda K, Uchimaru T, et al. Origin of attraction and directionality of the π/π interaction: model chemistry calculations of benzene dimer interaction. J Am Chem Soc 2002;124:104–12
   PubMed Web of Science ®Google Scholar
• Karplus PA, Diederichs K. Linking crystallographic model and data quality. Science 2012;336:1030–33
   PubMed Web of Science ®Google Scholar
• Lovell SC, Davis IW, Arendall WB III, et al. Structure validation by Cα geometry: φ, ψ and Cβ deviation. Proteins 2003;50:437–50
   PubMed Web of Science ®Google Scholar
• Burkey BF, Russell M, Wang K, et al. Vildagliptin displays slow tight-binding to dipeptidyl peptidase (DPP)-4, but not DPP-8 or DPP-9. Presented at 42nd EASD meeting, Copenhagen, Denmark 2006; September 14–17:abstract0788
   Google Scholar
• Furuta S, Smart C, Hackett A, et al. Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. Xenobiotica 2013;43:432–42
   PubMed Web of Science ®Google Scholar
• Yoshida T, Akahoshi F, Sakashita H, et al. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment 2 diabetes. Bioorg Med Chem 2012;20:5705–19
   PubMed Web of Science ®Google Scholar
• Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes. Diabetes 2005;54:2988–94
   PubMed Web of Science ®Google Scholar
• Rummey C, Metz G. Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site. Proteins 2007;66:160–71
   PubMed Web of Science ®Google Scholar
• Ninković DB, Andrić JM, Malkov SN, Zarić SD. What are the preferred horizontal displacements of aromatic–aromatic interactions in proteins? Comparison with the calculated benzene–benzene potential energy surface. Phys Chem Chem Phys 2014;16:11173–7
   PubMed Web of Science ®Google Scholar
• Ahn JH, Park WS, Jun MA, et al. Synthesis and biological evaluation of homopiperazine derivatives with β-aminoacyl group as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2008;18:6525–9
   PubMed Web of Science ®Google Scholar